Suven Life Sciences Ltd

A Biopharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally. Suven discovery research is focused on discovering and developing new chemical entities (NCEs), which are best in class central nervous system therapies for the treatment of cognitive disorders, major depressive disorders, sleep disorders, psychiatric disorders, pain and inflammation, gastrointestinal motility disorders. Research targets include serotonin 6 receptor, serotonin 4 receptor, histamine 3 receptor, Nicotinic acetylcholine (Alpha4beta2) receptor, muscarinic M1 receptor, muscarinic M4 receptor, multimodal (Dopaminergic and serotonergic receptor), and P2X purinoceptor 7 receptor